ALLO Allogene Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALLO

Price (delayed)

$3.04

Market cap

$514.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.09

Enterprise value

$420.59M

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by ...

Highlights
Allogene Therapeutics's debt has plunged by 100% from the previous quarter
The EPS has grown by 12% YoY and by 9% from the previous quarter
ALLO's quick ratio is up by 26% year-on-year but it is down by 2.1% since the previous quarter
ALLO's revenue is down by 39% year-on-year and by 4% since the previous quarter
The gross profit is down by 39% year-on-year and by 4% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allogene.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ALLO
Market
Shares outstanding
169.09M
Market cap
$514.04M
Enterprise value
$420.59M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1
Price to sales (P/S)
5,021.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,427.29
Earnings
Revenue
$95,000
EBIT
-$327.27M
EBITDA
-$313.07M
Free cash flow
-$239.25M
Per share
EPS
-$2.09
Free cash flow per share
-$1.52
Book value per share
$3.04
Revenue per share
$0
TBVPS
$4.1
Balance sheet
Total assets
$642.84M
Total liabilities
$130.6M
Debt
$0
Equity
$512.23M
Working capital
$422.04M
Liquidity
Debt to equity
0
Current ratio
12.38
Quick ratio
12.38
Net debt/EBITDA
0.3
Margins
EBITDA margin
-329,543.2%
Gross margin
100%
Net margin
-344,489.5%
Operating margin
-344,986.3%
Efficiency
Return on assets
-45.6%
Return on equity
-56.7%
Return on invested capital
-52.3%
Return on capital employed
-54%
Return on sales
-344,489.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALLO stock price

How has the Allogene Therapeutics stock price performed over time
Intraday
-9.79%
1 week
-13.39%
1 month
-28.64%
1 year
-43.39%
YTD
-5.3%
QTD
-31.99%

Financial performance

How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$95,000
Gross profit
$95,000
Operating income
-$327.74M
Net income
-$327.27M
Gross margin
100%
Net margin
-344,489.5%
The operating margin has dropped by 60% year-on-year
Allogene Therapeutics's net margin has plunged by 58% YoY
ALLO's revenue is down by 39% year-on-year and by 4% since the previous quarter
The gross profit is down by 39% year-on-year and by 4% since the previous quarter

Growth

What is Allogene Therapeutics's growth rate over time

Valuation

What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
1
P/S
5,021.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4,427.29
The EPS has grown by 12% YoY and by 9% from the previous quarter
ALLO's price to book (P/B) is 67% less than its 5-year quarterly average of 3.0 and 9% less than its last 4 quarters average of 1.1
Allogene Therapeutics's equity has decreased by 23% YoY and by 12% QoQ
ALLO's revenue is down by 39% year-on-year and by 4% since the previous quarter
The stock's price to sales (P/S) is 11% less than its last 4 quarters average of 5619.3

Efficiency

How efficient is Allogene Therapeutics business performance
The ROS has plunged by 58% YoY
ALLO's return on invested capital is down by 29% year-on-year and by 3% since the previous quarter
The return on equity has declined by 28% year-on-year and by 2.5% since the previous quarter
The return on assets has declined by 21% year-on-year and by 2.2% since the previous quarter

Dividends

What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLO.

Financial health

How did Allogene Therapeutics financials performed over time
ALLO's current ratio is up by 26% YoY
ALLO's quick ratio is up by 26% year-on-year but it is down by 2.1% since the previous quarter
Allogene Therapeutics's debt is 100% less than its equity
Allogene Therapeutics's debt has plunged by 100% from the previous quarter
The company's debt to equity has shrunk by 100% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.